GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO. METREX involved patients with a range of ...
The European Commission has approved two new delivery formats for Nucala (mepolizumab) – a pre-filled pen injector and a pre-filled safety syringe – that will allow patients with eosinophilic ...
Data from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful ...
Image Source: Zacks Investment Research GSK’s regulatory filing seeking the approval of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype was ...
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved ... indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic ...
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal ... for the treatment of adult patients with chronic rhinosinusitis with nasal polyps ...
“We are delighted that Nucala has been approved in China as a treatment for CRSwNP, a chronic condition for which new and effective treatments are needed. “Patients now have a non-surgical ...